Akebia Therapeutics Inc (AKBA)

$1.1

+0.01

(+0.92%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Akebia Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 56.19M → 32.60M (in $), with an average decrease of 42.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 614.0K → -17.98M (in $), with an average decrease of 3029.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 69.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 306.6%

Performance

  • $1.08
    $1.12
    $1.10
    downward going graph

    1.82%

    Downside

    Day's Volatility :3.44%

    Upside

    1.65%

    downward going graph
  • $0.78
    $2.48
    $1.10
    downward going graph

    29.08%

    Downside

    52 Weeks Volatility :68.54%

    Upside

    55.65%

    downward going graph

Returns

PeriodAkebia Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-27.15%
-1.8%
0.0%
6 Months
11.09%
10.1%
0.0%
1 Year
-2.65%
13.2%
0.0%
3 Years
-67.93%
17.0%
-21.4%

Highlights

Market Capitalization
228.5M
Book Value
- $0.13
Earnings Per Share (EPS)
-0.22
PEG Ratio
0.0
Wall Street Target Price
5.0
Profit Margin
-22.99%
Operating Margin TTM
-43.82%
Return On Assets TTM
-8.37%
Return On Equity TTM
-553.45%
Revenue TTM
187.2M
Revenue Per Share TTM
0.97
Quarterly Revenue Growth YOY
-18.5%
Gross Profit TTM
140.0M
EBITDA
4.0M
Diluted Eps TTM
-0.22
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.3
EPS Estimate Next Year
-0.33
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Akebia Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 354.55%

Current $1.10
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Akebia Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akebia Therapeutics Inc
Akebia Therapeutics Inc
-17.91%
11.09%
-2.65%
-67.93%
-78.22%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akebia Therapeutics Inc
Akebia Therapeutics Inc
NA
NA
0.0
-0.3
-5.53
-0.08
NA
-0.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akebia Therapeutics Inc
Akebia Therapeutics Inc
Buy
$228.5M
-78.22%
NA
-22.99%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • SATTER MANAGEMENT CO., L.P.

    7.73%
  • Vanguard Group Inc

    3.63%
  • Acadian Asset Management LLC

    3.30%
  • Renaissance Technologies Corp

    2.28%
  • BlackRock Inc

    1.49%
  • Millennium Management LLC

    1.24%

Company Information

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Organization
Akebia Therapeutics Inc
Employees
167
CEO
Mr. John P. Butler MBA
Industry
Health Technology

FAQs